Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease

Ihosvany Fernández Bello1, María T Álvarez, Francisco J López-Longo

  • 1Hematology Unit, Hospital Universitario La Paz-IdiPaz, Madrid, Spain.

Thrombosis and Haemostasis
|November 26, 2011
PubMed

Insights

Platelets release soluble CD40L (sCD40L), a key inflammatory mediator, which is elevated in Behçet disease (BD). Platelet matrix metalloproteinase-9 (MMP-9) drives sCD40L shedding and is upregulated by sCD40L, forming a positive feedback loop in BD inflammation.

Area of Science:

  • Immunology
  • Inflammation Biology
  • Vascular Biology

Background:

  • Platelets are a primary source of soluble CD40L (sCD40L), a critical inflammatory mediator.
  • Behçet disease (BD) is an autoinflammatory vasculitis with unclear pathogenesis.
  • Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, are implicated in inflammatory processes.

Purpose of the Study:

  • To investigate the role of platelet-derived sCD40L in Behçet disease (BD).
  • To explore the influence of platelet MMP-2 and MMP-9 on CD40L shedding.
  • To elucidate the potential feedback mechanism between sCD40L and MMP-9 in BD.

Main Methods:

  • Flow cytometry and aggregometry assessed platelet activation and aggregates.
  • ELISA measured plasma sCD40L, while Western blot analyzed cellular CD40L/CD40.
  • Gelatin zymography determined MMP activity; cultured MEG-01 cells studied sCD40L effects on MMP-9 expression.

Main Results:

  • BD patients exhibited higher plasma and platelet sCD40L levels compared to controls.
  • Elevated plasma and platelet MMP-9 levels were observed in BD patients; MMP-2 levels were unchanged.
  • Recombinant sCD40L treatment increased MMP-9 expression in MEG-01 cells, suggesting a feedback loop.

Conclusions:

  • Platelet MMP-9 mediates the shedding of sCD40L, contributing to elevated levels in BD.
  • sCD40L upregulates MMP-9 expression in megakaryocytes, establishing a positive feedback loop.
  • This sCD40L-MMP-9 axis may drive the chronic inflammation characteristic of Behçet disease.

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...